ReviewInternational journal of molecular medicine2026
Decoding miRNA‑146a: Mechanisms of action in cardiovascular diseases and endocrine metabolic disorders (Review).
Review in International journal of molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNA‑146a (miR‑146a) has emerged as a core regulatory molecule in inflammation and metabolism in recent years, and the present review systematically elucidates its critical role and regulatory mechanisms in cardiovascular diseases as well as endocrine and metabolic disorders. Evidence indicates that miR‑146a negatively regulates the nuclear factor‑κB inflammatory signaling pathway by targeting key molecules such as tumor necrosis factor receptor‑associated factor 6 and interleukin‑1 receptor‑associated kinase 1. This regulation impacts various pathophysiological processes, including immune response, inflammatory reactions, oxidative stress, cell apoptosis and proliferation, autophagy, and anti‑fibrosis. The molecule demonstrates a bidirectional dynamic regulatory feature, exhibiting either protective or maladaptive effects in different diseases and stages of disease, particularly in the progression of cardiovascular conditions (such as myocardial ischemia‑reperfusion injury and atherosclerosis) and endocrine and metabolic disorders (such as diabetes and its complications). Additionally, miR‑146a serves as a significant biomarker and therapeutic target. Future research should focus on further elucidating its cell‑ and disease course‑specific mechanisms while promoting the clinical translation of therapeutic strategies based on targeted delivery systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.